| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | KRT2A; KRT2E; KRT2B; KRT2P; K6A; KRT6D; K6B; KRTL1; KRT6E; K6IRS1; KB34; KRT6IRS1; K6IRS2; KB35; KRT6; KRT6IRS2; K6IRS3; KB36; KRT6IRS3; K6IRS4; KB37; KRT5C; KRT6IRS4; K6HF; KB18; K6L; KB38; KRT6L; SCL; CYK8; KRTHB4 |
| Entrez GeneID | 3849 |
| WB Predicted band size | Calculated MW: 65 kDa; Observed MW: 70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthetic peptide from human protein at AA range: 150-220 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇与Cytokeratin抗体相关的经典文献示例(注：内容为模拟概括，实际引用请核实原文)：
1. **文献名称**: "The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells"
**作者**: Moll R, et al.
**摘要**: 系统描述了人类细胞角蛋白(Cytokeratin)的分类及抗体特异性，阐明了不同亚型在上皮细胞、肿瘤组织及细胞系中的表达差异，为癌症病理诊断提供分子标记基础。
2. **文献名称**: "Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma using CK7 and CK20 antibodies"
**作者**: Nagase H, et al.
**摘要**: 通过Cytokeratin 7(CK7)和CK20抗体免疫组化分析，建立膀胱原发腺癌与结直肠转移癌的鉴别诊断方法，证实CK7-/CK20+模式对肠源性肿瘤的特异性。
3. **文献名称**: "Cytokeratin expression in human mammary gland: a review"
**作者**: Böcker W, Löning T.
**摘要**: 综述Cytokeratin抗体在乳腺癌研究中的应用，揭示不同亚型(如CK5/6、CK8/18)在乳腺正常组织、良性病变及恶性肿瘤中的表达模式及其预后意义。
4. **文献名称**: "Cytokeratin subtypes in diagnostic pathology"
**作者**: Ramaekers F, van Muijen G.
**摘要**: 探讨Cytokeratin抗体在病理诊断中的价值，强调其在鉴别癌与肉瘤、原发灶不明转移癌及微小病灶检测中的关键作用。
**提示**：建议通过PubMed或Web of Science检索最新文献，结合具体研究场景(如肿瘤类型、抗体亚型)筛选高相关性论文。
Cytokeratin antibodies are essential tools in both diagnostic pathology and biomedical research, targeting cytokeratins—a family of intermediate filament proteins expressed in epithelial cells. Cytokeratins are classified into Type I (acidic, CK9–CK20) and Type II (basic, CK1–CK8), which form heteropolymers to maintain cellular structural integrity. Their expression patterns vary across epithelial tissues, making them valuable markers for identifying tissue origin. For instance, CK7/CK20 profiles help distinguish adenocarcinomas (e.g., CK7+/CK20– in lung cancer vs. CK7–/CK20+ in colorectal cancer).
In diagnostics, these antibodies aid in detecting metastatic tumors by confirming epithelial origin, especially in poorly differentiated cancers. They also assess tumor progression, prognosis, and micrometastases in lymph nodes. Beyond clinical use, cytokeratin antibodies facilitate research on epithelial-mesenchymal transition (EMT), wound healing, and carcinogenesis. Subtype-specific antibodies (e.g., CK5/6. CK14) are critical in subclassifying breast cancers or squamous cell carcinomas.
Common detection methods include immunohistochemistry (IHC), Western blotting, and immunofluorescence. However, interpretation requires caution due to cross-reactivity or aberrant expression in non-epithelial tumors. Overall, cytokeratin antibodies bridge clinical diagnostics and molecular research, underscoring their versatility in understanding epithelial biology and disease.
×
